Comparative efficacy of pharmacological interventions on metabolic and hormonal outcomes in polycystic ovary syndrome: a Network Meta-Analysis of Randomized controlled trials

BMC Women s Health, Journal Year: 2025, Volume and Issue: 25(1)

Published: Feb. 15, 2025

Polycystic ovary syndrome (PCOS) is a common endocrine disorder associated with metabolic and hormonal abnormalities. This study aimed to evaluate the comparative efficacy of pharmacological interventions on these outcomes. We conducted systematic review network meta-analysis randomized controlled trials (RCTs) assessing treatments for PCOS. Searches in PubMed, MEDLINE, Embase, Web Science were up October 20, 2023. Eligible studies RCTs at least 12 weeks follow-up outcomes including body weight (BW), mass index (BMI), waist circumference (WC), testosterone, sex hormone-binding globulin (SHBG), lipid profiles, HOMA-IR, fasting blood glucose (FBG), insulin (FINS). Twenty-nine 1476 participants included. The combination standard therapy GLP-1 receptor agonists significantly reduced BW (MD= -3.44; 95% CI= -6.20 -0.67), BMI -2.05; -3.55 -0.55), WC -4.39; -6.75 -2.02) compared alone. Orlistat lowered testosterone (SMD= -2.16; -3.84 -0.48) increased HDL-C levels (SMD = 0.90; CI 0.02 1.79) placebo. also HOMA-IR -1.29; -2.38 -0.21) FBG -1.80; -3.04 -0.55) Combining offers superior improving women effectively reduces androgen levels. These findings support use pharmacotherapy comprehensive management

Language: Английский

---

Metabolic Regulation and Cardiorenal Protection: Deciphering the Potential and Multi-Target Mechanisms of Jiangtang Qingre Formula for Type 2 Diabetes Management

Published: Jan. 1, 2025

Language: Английский

---

Coronary atherosclerotic plaque modification: the present and the future

Expert Review of Cardiovascular Therapy, Journal Year: 2025, Volume and Issue: 23(3), P. 65 - 71

Published: March 4, 2025

Introduction Coronary atherosclerosis, marked by lipid deposition and inflammation, drives cardiovascular morbidity. Traditional treatments focus on reduction, yet newer therapies target plaque composition, aiming to enhance stability prevent coronary events.

Language: Английский

---

Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes Mellitus: A Scoping Review and Expert Insights for Clinical Practice Utilizing the Nominal Group Technique

Diabetes Therapy, Journal Year: 2025, Volume and Issue: unknown

Published: March 24, 2025

Treating type 2 diabetes has shifted from a gluco-centric approach to broader cardio-renal-metabolic strategy, driven by the use of disease-modifying medications. Traditionally, management relied on stepwise medication addition based failures in glucose control. However, benefits and risks combining glucagon-like peptide-1 receptor agonists (GLP1-RAs) sodium-glucose cotransporter inhibitors (SGLT2is) remain inadequately understood. This study conducted scoping review examine available clinical research GLP1-RAs SGLT2is. Additionally, nominal group technique was used gather insights medical experts different areas regarding combined therapy's daily use, concerns, limitations. The followed guidelines outlined Joanna Briggs Institute Reviewer's Manual PRISMA-ScR (Preferred Reporting Items for Systematic Reviews Meta-Analyses Extension Scoping Reviews). final report includes 50 studies. most common designs are observational median (IQR) number patients across studies 355 (1295). Studies reporting metabolic outcomes were common. follow-up time ranges 1.5 60 months. Although limited, evidence seems support agreed that underlying mechanisms appear synergistic rather than antagonistic outcomes. Combining therapy is treatment may occur naturally everyday practice. Limited suggests SGLT2is/GLP1-RAs can potentially improve but not all Quality better-defined paramount guide selection therapy.

Language: Английский

---

Efficacy and Safety of Tirzepatide for Weight Management in Non-Diabetic Obese Individuals: A Narrative Review

Obesities, Journal Year: 2025, Volume and Issue: 5(2), P. 26 - 26

Published: April 18, 2025

Obesity represents a global health challenge, with critical and urgent need for long-term, sustainable management strategies. Tirzepatide is novel dual glucose-dependent insulinotropic polypeptide (GIP) glucagon-like peptide-1 (GLP-1) receptor agonist. At first approved the treatment of type 2 diabetes mellitus, tirzepatide one latest clinically commercially available pharmacological options obesity management. This narrative review aimed to synthesize existing clinical evidence on efficacy safety in non-diabetic obese individuals. A comprehensive literature search was conducted using PubMed, Scopus, Web Science, ClinicalTrials.gov, Google Scholar databases identify relevant trials, meta-analyses, original studies assessing weight-loss impact from 2022 onwards. Synthesized indicated that achieved up 20.9% weight loss over 72 weeks (SURMOUNT-1), 18.4% after lifestyle intervention (SURMOUNT-3), 17.5% Chinese adults (SURMOUNT-CN), 25.3% continued 88 (SURMOUNT-4). Meta-analyses confirmed higher odds ≥5–20% versus semaglutide liraglutide, significantly reducing body mass index, waist circumference, blood pressure, atherosclerotic cardiovascular disease risk. Health-related quality life improved greater loss, gastrointestinal side effects (nausea, diarrhea, constipation) were common but mild moderate, <5% discontinuation. significant cardiometabolic benefits, individuals, further research needed long-term efficacy, safety, application.

Language: Английский

---

Eine neue Ära der Diabetestherapie – Komorbiditäten im Fokus!

Gefässchirurgie, Journal Year: 2025, Volume and Issue: unknown

Published: April 28, 2025

---

Cardiovascular and renal effects of the combination therapy of a GLP-1 receptor agonist and an SGLT2 inhibitor in observational real-life studies

Diabetes & Metabolism, Journal Year: 2024, Volume and Issue: unknown, P. 101594 - 101594

Published: Nov. 1, 2024

Language: Английский

---

SGLT2i and GLP1RA effects in patients followed in a hospital diabetology consultation

Expert Review of Clinical Pharmacology, Journal Year: 2024, Volume and Issue: 17(11), P. 1081 - 1088

Published: Oct. 25, 2024

Background We aimed to investigate the effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1RA) in patients with type diabetes mellitus (T2DM) clinical practice.

Language: Английский

---